SAN FRANCISCO, April 24, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that data from the Company's Phase 2 efficacy study of Dimebon(TM) in Alzheimer's disease will be presented for the first time in the United States at the American Academy of Neurology's 59th Annual Meeting in Boston on Thursday, May 3, at 4:15 p.m. Eastern time. The presentation will include new data from both the mild and moderate subgroups of patients with Alzheimer's disease. Medivation will hold a teleconference on Friday, May 4, at 9:00 a.m. Eastern time with David Hung, M.D., president and chief executive officer of Medivation, Lynn Seely, M.D., chief medical officer, and Rachelle S. Doody, M.D., Ph.D., lead investigator, to discuss the data.
Dr. Doody will present the data (abstract #S51.003), Dimebon Improves Cognition, Function and Behavior in Patients with Mild-Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Study, during the "Aging and Dementia" session of the conference. Dr. Doody holds the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston.
In addition, these data have been selected by the American Academy of Neurology for inclusion in the Scientific Topic Highlights session on Thursday, May 3, at 6:00 p.m. Eastern time. During this session, expert moderators will summarize the most interesting and relevant research at the meeting in a particular topic.
To participate in the live call by telephone, please dial 800-289-0485 from the U.S. or 913-981-5518 internationally. Individuals interested in listening to the live call via webcast may do so by visiting www.medivation.com. A replay of the webcast will be available on the Company's website for 3 0 days.
Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. Medivation is currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington's diseases.
Six-month results from the Phase 2 efficacy study demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior. Dimebon was well tolerated in the study.
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to www.medivation.com.
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Liti gation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064, for Medivation, Inc.
Web site: http://www.medivation.com//
Ticker Symbol: (NASDAQ-NMS:MDVN)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company